1	Mark C. Holscher (SBN 139582)	QUINN EMANUEL URQUHART &
2	KIRKLAND & ELLIS LLP	SULLIVAN, LLP
2	555 South Flower Street, Suite 3700 Los Angeles, CA 90071	Diane M. Doolittle (Bar No. 142046) dianedoolittle@quinnemanuel.com
3	Telephone (213) 680-8400	Yury Kapgan (Bar No. 218366)
	Facsimile: (213) 680-8500	yurykapgan@quinnemanuel.com
4	Email: mark.holscher@kirkland.com	Kyle Batter (Bar No. 301803)
ا ہے	G1 1 1 W W (GD) (222.45)	kylebatter@quinnemanuel.com
5	Christopher W. Keegan (SBN 232045)	555 Twin Dolphin Drive, 5th Floor
6	Anna Terteryan (SBN 300368) KIRKLAND & ELLIS LLP	Redwood Shores, California 94065 Telephone: (650) 801-5000
	555 California Street, Suite 2700	Facsimile: (650) 801-5000
7	San Francisco, CA 94104	(
	Telephone: (415) 439-1400	David M. Elihu (Bar No. 303043)
8	Facsimile: (415) 439-1500	davidelihu@quinnemanuel.com
	Email: chris.keegan@kirkland.com	865 South Figueroa Street, 10th Floor
9	Email: anna.terteryan@kirkland.com	Los Angeles, California 90017
10	Gabor Balassa (admitted pro hac vice)	Telephone: (213) 443-3000 Facsimile: (213) 443-3100
	Ryan Moorman (admitted <i>pro hac vice</i> )	1 desimile. (213) 113 3100
11	KIRKLAND & ELLIS LLP	Counsel for Plaintiff and Counter-Defendant
	333 West Wolf Point Plaza	Nektar Therapeutics
12	Chicago, IL 60654	
13	Telephone: (312) 862-2000 Facsimile: (312) 862-2200	
13	Email: gbalassa@kirkland.com	
14	Email: ryan.moorman@kirkland.com	
15	Counsel for Defendant and Country Claimant	
13	Counsel for Defendant and Counter-Claimant Eli Lilly and Company	
16	211 2111y una company	
17	UNITED STATES DISTRICT COURT	
	NODTHEDN DISTRICT OF CALLEODNIA	
18		
19	SAN FRANCISCO DIVISION	
20		
_	NEKTAR THERAPEUTICS,	CASE NO. 3:23-CV-03943-JD
21	Plaintiff/Counter-Defendant,	STIPULATION AND [PROPOSED] ORDER
,,	Trainer Berendant,	MODIFYING SEALING PROCEDURES
22	v.	RELATED TO DISPOSITIVE MOTIONS
23		AND DAUBERT MOTIONS
	ELI LILLY & CO.,	Judge: Hon. James Donato
24	Defendant/Counter-Claimant.	Judge: Hon. James Donato
25	Defendant Counter Claimant.	
ر ک		_
26		
27		
28		
- 1	I.	

Pursuant to Civil Local Rule 7-12, Plaintiff Nektar Therapeutics ("Plaintiff") and Defendant Eli Lilly and Company ("Defendant"), by and through their undersigned counsel, hereby stipulate and agree as follows:

WHEREAS, on February 11, 2025, this Court entered an Amended Scheduling Order setting the last day to file dispositive motions and *Daubert* motions as May 22, 2025 (ECF No. 148);

WHEREAS, pursuant to Paragraph 31 of this Court's Standing Order for Civil Cases ("Paragraph 31"), the parties anticipate that "voluminous or multiple administrative motions to seal would be filed if normal procedures were followed" for the round of briefing on any dispositive motions and *Daubert* motions;

WHEREAS, Paragraph 31 further encourages parties to indicate in their motions to seal filed concurrently with briefs that a "more fulsome and revised motion to seal will be forthcoming after the completion of briefing" ("Omnibus Sealing Motion");

WHEREAS, pursuant to Paragraph 31, an Omnibus Sealing Motion will supersede any interim sealing motion that would ordinarily accompany the parties' opening briefs, opposition briefs, and reply briefs on dispositive motions and *Daubert* motions, the parties believe that it will be most efficient for the Court, and the parties, to address all sealing issues in Omnibus Sealing Motions to be filed following the initial filing of these materials;

WHEREAS, the parties have conferred and jointly propose, subject to the Court's approval, certain modifications to the Court's procedures for sealing of filings associated with any dispositive motion briefing, or *Daubert* motion briefing, for efficiency and to reduce burden on the Court;

NOW THEREFORE, the parties hereby stipulate and agree, subject to the Court's approval, as follows:

- 1. The parties shall file redacted versions of all dispositive motion briefing and *Daubert* motion briefing, as separate entries on the docket; and
- 2. The parties shall also contemporaneously file unreducted copies of all documents on the docket provisionally under seal, along with a short interim sealing motion indicating that the reasons sought for sealing will be set forth in an Omnibus Sealing Motion; and

- 3. The parties shall jointly file Omnibus Sealing Motions covering all dispositive motions briefing and *Daubert* briefing, 30 days after the last reply brief is filed;
- 4. For briefing on other motions or other filings not specifically referenced in this stipulation that the parties anticipate would involve voluminous or multiple administrative motions to seal if normal procedures were followed, the parties may agree to use the Omnibus Sealing Motion procedure set forth in this stipulation without seeking further authorization from the Court.

DATED: May 19, 2025 Respectfully submitted,

KIRKLAND & ELLIS LLP

## s/Ryan Moorman

Ryan Moorman

Counsel for Defendant and Counter-Claimant Eli Lilly and Company

DATED: May 19, 2025 Respectfully submitted,

QUINN EMANUEL URQUHART & SULLIVAN, LLP

s/ Yury Kapgan

Yury Kapgan

Counsel for Plaintiff and Counter-Defendant Nektar Therapeutics

## ATTESTATION PURSUANT TO CIVIL L.R. 5-1(I)(3)

I, Ryan Moorman, am the ECF user whose user ID and password are being used to file this document. I hereby attest that concurrence in the filing of this document has been obtained from each of the other signatories.

/s/ Ryan Moorman
Ryan Moorman

PURSUANT TO STIPULATION, IT IS SO ORDERAD:

3 Dated May 22 , 2025

JAME DONATO UNIT D STATES DISTRICT COURT JUDGE

STIPULATION AND [PROPOSED] ORDER RELATED TO SEALING PROCEDURES